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Abstract
The objective of this study was to investigate the fat and carbohydrate metabo-
lism in a patient with propionic acidemia (PA) during exercise by means of
indirect calorimetry and stable isotope technique. A 34-year-old patient with
PA performed a 30-minute submaximal cycle ergometer test. Data were com-
pared to results from six gender- and age-matched healthy controls. Main find-
ings are that the patient with PA had impaired lipolysis, blunted fatty acid
oxidation, compensatory increase in carbohydrate utilization, and low work
capacity. Our findings indicate that PA should be added to the list of metabolic
myopathies.
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1 | INTRODUCTION
Propionic acidemia (PA) is a rare organic aciduria caused
by a mutation in either the PCCA or PCCB genes (OMIM
numbers *232000 and *232050) causing deficiency of the
enzyme propionyl-CoA carboxylase (PCC).1 Propionyl-
CoA is a metabolite arising from the catabolism of the four
amino acids valine, threonine, methionine, and isoleucine,
as well as odd-chain fatty acids and cholesterol. PCC catal-
yses the conversion of propionyl-CoA to D-methylmalonyl-
CoA, which in turn is converted to succinyl-CoA
and enters the tricarboxylic acid (TCA) circle.1 PA
causes an accumulation of alternative metabolites from
propionyl-CoA.1
Most patients present with drowsiness and poor feed-
ing within hours to days postpartum. If the metabolic
decompensation is not treated, progressive encephalopa-
thy with neurological damage will ensue.2 Metabolic cri-
sis often include acidosis and hyperammonaemia.3
Approximately, 25% of the patients present after 1 year of
age with either symptoms similar to the neonatal onset
type or a more chronic, progressive form.2
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Metabolic decompensation may occur without any
apparent reason but is mostly caused by catabolic stress
(eg, infection, trauma, surgery, exercise). Treatment of
these acute episodes of metabolic decompensation is pri-
marily symptomatic, whereas long-term prophylactic treat-
ment consists of dietary restriction of propiogenic amino
acids, L-carnitine supplementation and metronidazole.3-5
In addition to the above-mentioned symptoms, all the
six patients in our clinic with PA and the related disorder
methylmalonic aciduria report exercise intolerance. As
exercise intolerance has never been investigated in PA,
the objective of this study was to examine the metabolism
of carbohydrates and fatty acids during exercise in a
patient with PA.
2 | METHODS
2.1 | Ethical approval
All participants signed an informed consent form. The
study was conducted according to the Helsinki Declara-
tion, approved by the Danish National Committee on
Health Research Ethics (H-15015150) and registered at
https://clinicaltrials.gov/ (NCT02635269).
2.2 | Subjects
2.2.1 | Patient
A 34-year-old woman with biochemically verified PA was
included (Table 1). She was diagnosed 2 years old and has
been followed closely at our clinic since. She holds a part-
time job and lives a close to normal everyday life without
adhering to any strict diet nor any other treatments. She
does, however, experience both fatigue and exercise intol-
erance. The latter presents as stiffness and heaviness of
the thigh and calf muscles during exercise. Echocardiogra-
phy had showed left ventricular hypertrophy and near
normal left ventricular ejection fraction at 45%-50%.
Only one of five patients with PA in our clinic had
the sufficient age and level of compliance to participate
in the study. This patient was the most mildly affected in
our clinic, the other four patients were either unable to
perform cycle exercise testing or reported they could not
overcome to participate in the study.
2.2.2 | Healthy controls
Six healthy gender- and age-matched subjects from a pre-
vious study6 were included as healthy controls
(HC) (Table 1). Methods pertaining to the HC are
described in the above-mentioned study.6
2.3 | Experimental protocol
Stable isotope tracers were prepared as previously
described.7 The patient came to the laboratory in the
morning and received a breakfast meal. Two intravenous
catheters were inserted in distal veins in the arms. After
blood and air sampling, infusions of [6.6-2H2]-glucose
(0.0026 mg kg−1 min−1, primed with 2.44 mg kg−1 (99%
enriched, Cambridge Isotope Laboratories, Andover,
MA) and [U-13C]-palmitate (0.0728 mg kg−1 min−1,
primed with 0.085 mg kg−1 of NaH13CO3 [98% enriched,
Cambridge Isotope Laboratories, Andover, MA]) were
started using a Gemini PC2 Pump (IMED, San Diego,
CA). After a basal infusion for 2 hours, the rate was dou-
bled, and the patient performed a 30-minute submaximal
exercise test on a cycle ergometer (Excalibur, Lode,
Gronningen, The Netherlands). Heart rate and perceived
exertion (Borg score) were noted every second minute.8
2.4 | Sampling and analysis
Samples of blood and expired air were collected before
start of infusion and every 10 minutes from 20 minutes
before the test started until the test stopped.
Prior to blood sampling, the arm was heated with a
heating pad to ensure arterialization of the blood. Blood
for measurements of glucose and lactate was sampled in
heparinized syringes and analyzed immediately on an
ABL90 flex (Radiometer, Bronshoj, Denmark). The
remaining blood samples were transferred to vials with
ethylenediamine tetraacetic acid and spun at 4C for
10 minutes. Plasma samples were stored in a −80C
freezer until analysis. Free fatty acids (FFA) were analyzed
with Wako NEFA-HR (2) (Fujifilm Wako Chemicals
Europe GmbH, Germany). Plasma carnitine level was ana-
lyzed at the Metabolic Laboratory at the Department of
Clinical Genetics, Rigshospitalet, Copenhagen.
SYNOPSIS
This study shows impaired energy metabolism in
a patient with propionic acidemia indicating that
this disease should be considered a metabolic
myopathy.
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FIGURE 1 Propionic acidemia (PA) patient (black bars) and
six healthy controls (grey bars). Values for healthy controls
presented as mean + SD. A, Rate of oxidation (Rox) of palmitate
at rest and at 30-minute exercise. B, Plasma palmitate
concentration at rest and during exercise. C, Fatty acid oxidation
(FAO) rate at rest and at 30-minute exercise. D, Respiratory
exchange rate (RER) at rest and during exercise. E, Total
carbohydrate oxidation (CHO) at rest and at 30-minute
exercise. F, Rate of appearance (Ra) of palmitate at rest and
during exercise
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Air samples were collected in a nondiffusible 15-L
Douglas bag (Hans Rudolph Inc., Shawnee, KS), and
transferred to evacuated Exetainer Breath Vials
(Labco Limited, Ceredigion, UK). Plasma samples of
glucose and palmitate tracer as well as the breath
samples were analyzed at Clinical Metabolomics Core
Facility, Rigshospitalet, Copenhagen, as previously
described.9,10
Measurements of gas exchanges were performed with
a Cosmed Quark CPET (Cosmed, Milan, Italy).
2.5 | Calculations and statistical analysis
Tracer calculations were done as previously described.7
Fatty acid oxidation (FAO) rates (μmol kg−1 min−1) were
calculated as follows:
1:695*VO2−1:701*VCO2ð Þ
860
gmol−1
 
*1 000 000
 
kg−1
 
*3:
Carbohydrate oxidation (CHO) rates (μmol
kg−1 min−1) were calculated as follows:
4:585×VCO2−3:226×VO2
180
gmol−1
 
× 1 000000
 
kg−1
Values for HC are presented as mean ± SD.
3 | RESULTS
Demographic data are described in Table 1. The PA
patient had a higher heart rate and Borg score during
exercise compared to HC.
3.1 | Fat and carbohydrate metabolism
FAO and palmitate oxidation were normal at rest, but
the normal increase during exercise was blunted in the
TABLE 2 Plasma metabolites, substrate turnover, and gas exchange in the PA patient vs HC
Patient Healthy controls
Rest 30 min Rest 30 min
Plasma metabolites
FFA (μmol L−1) 456 380 402 ± 219 518 ± 351
Glycerol (μmol L−1) 71 87 140 ± 37a 160 ± 47a
Alanine (μmol L−1) 261 424 260 ± 54a 240 ± 51a
Palmitate (μmol L−1) 115 78 147 ± 65 225 ± 108
Glucose (mmol L−1) 4.8 3.8 5.3 ± 0.8 5.1 ± 0.4
Lactate (mmol L−1) 0.87 4.74 0.93 ± 0.23a 0.76 ± 0.30b
Substrate turnover
Palmitate Ra (μmol kg−1 min−1) 0.7 0.6 2.5 ± 0.8 3.6 ± 1.5
Palmitate Rd (μmol kg−1 min−1) 0.7 0.6 2.5 ± 0.8 3.5 ± 1.5
Palmitate Rox (μmol kg−1 min−1) 1.2 1.3 0.7 ± 0.3 1.9 ± 1.2
Total fatty acid Rox (μmol kg−1 min−1) 7.4 5.6 4.0 ± 1.3 9.3 ± 4.2
Glucose Rd (μmol kg−1 min−1) 19.9 28.1 16.3 ± 0.9a 14.0 ± 0.3a
CHO (μmol kg−1 min−1) 7.8 71.2 8.7 ± 4.3 48.0 ± 15.2
RER 0.77 0.92 0.80 ± 0.05 0.87 ± 0.06
Gas exchange
VO2 (mL min
−1) 290 697 217 ± 43 733 ± 79
VCO2 (mL min
−1) 221 643 174 ± 35 633 ± 67
Note: Values for healthy controls presented as mean ± SD.
Abbreviations: CHO, carbohydrate oxidation; FFA, free fatty acids; HC, healthy controls; PA, propionic acidemia; Ra, rate of appearance; RER, respiratory
exchange rate; Rd, rate of disappearance; Rox, rate of oxidation; VCO2, carbon dioxide excretion; VO2, oxygen uptake.
an = 4.
bn = 3.
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patient (Figure 1). Furthermore, plasma palmitate and
plasma FFA increased during exercise in the HC but not
in the PA patient. In line with this, total CHO and respi-
ratory exchange rate (RER) increased to higher values in
the PA patient vs HC (Table 2).
3.2 | Plasma metabolites
Plasma lactate levels rose more than fivefold in the PA
patient, whereas they remained unchanged in the HC
(Table 2). Plasma carnitine was low in the patient. Oxy-
gen uptake was comparable between HC and the patient
(Table 1).
4 | DISCUSSION
The primary objective of this study was to investigate the
carbohydrate and fat metabolism during exercise in a
patient relatively mildly affected with PA using stable iso-
tope technique and indirect calorimetry. Main findings
are that the patient with PA had (a) impaired lipolysis,
(b) a blunted FAO, (c) a compensatory increased carbo-
hydrate utilization, and (d) a low work capacity.
Surprisingly, the normal exercise-induced increase in
plasma palmitate and FFA levels was blunted in the PA
patient. This impaired lipolysis and lack of substrates for
FAO most likely causes the blunted increase in palmi-
tate oxidation and total FAO. Findings are similar to
those reported in a patient with neutral lipid storage dis-
ease.11 However, the lack of substrates might not be the
only reason for the blunted FAO in the PA patient, since
the plasma carnitine concentration was low, possibly
leading to impaired transport of long-chain fatty acids
into the mitochondria for FAO. Carnitine levels are
often low in untreated PA patients due to elevated excre-
tion of carnitine bound to organic acids.4 Furthermore, a
number of in vitro studies indicate that the TCA cycle is
impaired due to inhibited enzymes; propionyl-CoA and
its metabolites have been shown to inhibit various mito-
chondrial enzymes, including pyruvate dehydrogenase
complex,12 α-ketoglutarate dehydrogenase complex,12
OXPHOS complex III,12 succinate-CoA ligase,13 citrate
synthase,14 aconitase,14 and isocitrate dehydrogenase.14
This might also contribute to the blunted FAO.
Both total CHO and RER increased to a larger extent
in the patient vs HC, indicating that the patient relies
more on carbohydrates as energy source than the HC. The
patient had a low work capacity as demonstrated by her
high mean heart rate of 156 beats per minute during the
30-minute, low-level (25 W) constant workload exercise
bout. Deconditioning secondary to limited physical
activity could influence this poor performance but cannot
alone explain this marked reduction in work capacity. A
low work capacity has also been observed in a patient
with methylmalonic aciduria,15 which is a similar disorder
caused by a defect in the enzyme methylmalonyl-CoA
mutase situated downstream from PCC, suggesting a
mutual pathophysiology pertaining to the low workload.
Another clinically comparable patient group are patients
with McArdle disease (glycogen storage disease V), who
also have a low workload capacity.16,17 They have an
impaired or most often completely blocked breakdown of
muscular glycogen.18 During exercise, the FAO in
McArdle patients initially rise to compensate for the lack
of energy-substrates from muscular glycogen. Though the
plasma FFA levels increase throughout exercise, the FAO
rate remains at the level achieved during the first part of
exercise and is unable to fully compensate for the energy
shortage6 This is probably due to lack of substrates in the
TCA cycle6,19 which together with the blocked glycogenol-
ysis results in the low oxidative capacity and work capac-
ity. A possible explanation for the low work capacity in
the PA patient could be a similar shortage of substrates in
the TCA cycle.
In conclusion, we found impaired lipolysis, blunted
FAO, elevated carbohydrate utilization, and low work
capacity in a patient relatively mildly affected by
PA. Same symptoms characterise our other more severely
affected patients with PA, and our results suggest that PA
should be considered a metabolic myopathy. However,
further investigations are required to confirm these novel
findings of perturbed fat metabolism in both mildly and
more severely affected patients with PA.
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